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Abstract
The Vpu accessory protein promotes HIV-1 release by counteracting Tetherin/BST-2, an interferon-regulated restriction factor,
which retains virions at the cell-surface. Recent reports proposed b-TrCP-dependent proteasomal and/or endo-lysosomal
degradation of Tetherin as potential mechanisms by which Vpu could down-regulate Tetherin cell-surface expression and
antagonize this restriction.In all of thesestudies, Tetherin degradation did not, however, entirelyaccountfor Vpuanti-Tetherin
activity. Here, we show that Vpu can promote HIV-1 release without detectably affecting Tetherin steady-state levels or
turnover, suggesting that Tetherin degradation may not be necessary and/or sufficient for Vpu anti-Tetherin activity. Even
though Vpu did not enhance Tetherin internalization from the plasma membrane (PM), it did significantly slow-down the
overall transport of the protein towards the cell-surface. Accordingly, Vpu expression caused a specific removal of cell-surface
Tetherin and a re-localization of the residual pool of Tetherin in a perinuclear compartment that co-stained with the TGN
marker TGN46 and Vpu itself. This re-localization of Tetherin was also observed with a Vpu mutant unable to recruit b-TrCP,
suggestingthatthis activity is taking place independently from b-TrCP-mediated trafficking and/or degradation processes.We
alsoshow thatVpuco-immunoprecipitateswith Tetherin and thatthis interactioninvolvesthe transmembranedomains of the
two proteins. Importantly, this association was found to be critical for reducing cell-surface Tetherin expression, re-localizing
the restriction factor in the TGN and promoting HIV-1 release. Overall, our results suggest that association of Vpu to Tetherin
affectsthe outwardtraffickingand/orrecyclingofthe restrictionfactorfromthe TGNandasaresultpromotesitssequestration
away from thePMwhere productive HIV-1assemblytakesplace.This mechanism of antagonism thatresults inTGN trapping is
likely to be augmented by b-TrCP-dependent degradation, underlining the need for complementary and perhaps synergistic
strategies to effectively counteract the powerful restrictive effects of human Tetherin.
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Introduction
Recent advances in retrovirology have revealed that mamma-
lian cells do not always provide a hospitable environment for the
replication of viruses that parasitize them. It is indeed becoming
increasingly clear that mammalian cells express a variety of
molecules and activities that interfere with specific steps of the
replication cycle of retroviruses and other viruses [1]. Among these
so-called restriction factors, the cellular protein CD317/BST-2/
HM1.24, also designated as Tetherin in reference to its ability to
tether HIV-1 virions to infected cells, was recently identified as a
potent inhibitor of the release step of retroviruses [2,3]. Tetherin is
a heavily glycosylated type II integral membrane protein with an
unusual topology in that it harbors two completely different types
of membrane anchor at the N- and C-terminus; it is composed of a
short N-terminal cytoplasmic tail linked to a transmembrane
anchor (TM), an extracellular domain that include three cysteine
residues important for dimerization, a predicted coiled-coil and a
putative C-terminal glycophosphatidyl-inositol (GPI)-linked lipid
anchor that is believed to ensure incorporation of Tetherin into
cholesterol-rich lipid rafts [4,5]. Tetherin inhibits the release of
widely divergent enveloped viruses, including members of the
lentivirus (primate immunodeficiency viruses), gammaretroviruses
(murine leukemia virus), spumaretrovirus (foamy virus), arenavirus
(Lassa virus), filovirus (Ebola and Marburg virus) families as well as
Kaposi’s sarcoma herpesvirus (KSHV) [2,3,6,7,8,9,10]. This
broad-spectrum inhibition of enveloped virus particle release by
Tetherin indicates that this restriction is unlikely to require specific
interactions with viral proteins. In that regard, recent evidence
indicates that Tetherin configuration rather than primary
sequences is critical for antiviral activity since an entirely artificial
Tetherin-like protein consisting solely of domains from three
proteins that were analogous to Tetherin in terms of size and
topology but lacking sequence homology with native Tetherin,
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[11]. Tetherin-mediated restriction of virus particle release is
believed to occur at sites of virus particle assembly at the plasma
membrane since a strong co-localization between Tetherin and
nascent particles generated from retroviral or filoviral structural
proteins was observed at the cell-surface [7,12]. In fact, recent
findings using the artificial Tetherin-like protein support a model
of restriction in which Tetherin directly cross-links virions to the
plasma membrane [11]. Under basal conditions, Tetherin is
expressed in B and T cells, plasmacytoid dendritic cells and
myeloid cells and many transformed cell lines [2,13,14,15,16]. In
addition, Tetherin expression is induced in many cell-types by type
I and type II interferon (IFN), which suggests that it might be an
important component of a broader antiviral innate immune
defense [2,13,17]. In response to this restriction, many viruses
express Tetherin antagonists such as KSHV K5, Ebola virus
envelope glycoprotein (GP), simian immunodeficiency virus
(SIVmac/smm) Nef, HIV-2 Env, SIVtan Env and HIV-1 viral
protein U (Vpu), which was the first anti-Tetherin factor identified
[2,3,9,10,18,19,20,21,22].
Vpu is an oligomeric type 1 integral membrane protein with two
major activities during HIV-1 infection [23]. It contributes to the
down-regulation of the CD4 receptor by targeting newly
synthesized CD4 molecules that are bound to envelope glycopro-
teins (Env) in the endoplasmic reticulum (ER) for degradation by
the ubiquitin-proteasome system [24,25]. This degradation
process relies on Vpu ability to associate with CD4 and to recruit
b-TrCP, a component of the SCF
b-TrCP E3 ubiquitin (Ub) ligase,
via phosphorylation of serines 52 and 56 within its DSGWXS
b-TrCP recognition motif [26,27]. In addition, Vpu promotes
HIV-1 particle release by suppressing human Tetherin activity in
restrictive Tetherin-expressing cells such as epithelial cell lines
(HeLa), T cell lines (Jurkat, CEM) and primary T lymphocytes and
macrophages [2,3,17]. In contrast, no effect of Vpu is observed in
permissive human cell lines devoid of Tetherin expression such as
HEK 293T and HT1080. Interestingly, Vpu does not exert its
anti-Tetherin activity in non-human cell lines regardless of their
Tetherin expression levels [6,28]. Indeed, although Tetherin
variants found in rhesus macaques, African green monkeys (agm)
and mouse cells are able to inhibit HIV-1 particle release, they are
resistant to antagonism by HIV-1 Vpu [29,30]. Analysis of
Tetherin variants encoded by different species highlighted
positively selected determinants in the Tetherin TM domain
responsible for conferring sensitivity to Vpu antagonism
[29,30,31,32]. The mechanism by which Vpu counteracts
Tetherin antiviral activity on HIV-1 particle release is still a
matter of debate. Vpu was found to decrease the expression of
Tetherin at the cell-surface [3] and to prevent Tetherin and Gag
co-localization at sites of particle assembly [7,12], suggesting that
removal of Tetherin from its site of tethering action could underlie
the mechanism by which Vpu counteracts this cellular restriction,
although this model has lately been challenged [33]. Recently, a
series of reports proposed proteasomal and/or endo-lysosomal
degradation of Tetherin through a b-TrCP-dependent process as
potential mechanisms by which Vpu antagonizes Tetherin
antiviral activity [12,20,30,31,34,35]. However, in all of these
studies, Vpu-induced Tetherin degradation did not entirely
account for the anti-Tetherin activity of Vpu. Thus, the precise
mechanism(s) through which Vpu antagonizes Tetherin is yet to be
elucidated.
In this study, we investigated the effect of Vpu on Tetherin
expression and trafficking to obtain a better insight into the
mechanism through which Vpu antagonizes Tetherin-mediated
restriction of HIV-1 particle release. Here, we provide evidence
that Vpu can promote HIV-1 particle release without affecting the
total steady-state levels or the turnover rate of Tetherin. We
further show that even though Vpu did not enhance Tetherin
internalization from the plasma membrane, it did significantly
slow-down the transport of the restriction factor towards the cell-
surface. Notably, expression of Vpu led to a specific removal of
cell-surface Tetherin and a re-localization of the residual pool of
Tetherin to a perinuclear compartment that extensively over-
lapped with the TGN. Finally, we show that Vpu and Tetherin
associate most probably via their TM domains and provide
evidence that this association is necessary to relocate Tetherin
from the cell-surface to the TGN and to counteract its restrictive
activity on HIV-1 release. Overall, our results are consistent with a
model whereby antagonism of Tetherin by Vpu involves
sequestration of the restriction factor in a perinuclear compart-
ment, away from virus assembly sites on the plasma membrane, a
process that could be augmented by the induction of Tetherin
degradation.
Results
Vpu can promote HIV-1 particle release without altering
the steady-state levels or turnover of Tetherin
To assess whether the reduction of Tetherin levels by Vpu was
necessary and sufficient to promote efficient HIV-1 particle
release, we analyzed the steady-state levels of exogenously-
expressed HA-Tetherin in permissive HEK 293T cells in
conditions where varying levels of virally-encoded Vpu was co-
expressed (Fig. 1A). This cellular system was previously used to
evaluate the effect of Vpu on Tetherin steady-state levels
[30,31,34]. At low Vpu expression levels (1 mg of Vpu+ proviral
construct), the levels of Tetherin were essentially similar to those
detected in absence of Vpu (1 mg of Vpu-defective proviral
construct) (compare lane 5 with lane 6), while at higher levels of
Vpu expression (2 mg of Vpu+ proviral construct), they were
Author Summary
Restriction factors are cellular proteins that interfere with
the multiplication and transmission of viruses and are
therefore important components of natural immunity.
Tetherin (also known as BST-2) is a recently identified
restriction factor that traps viruses at the cell-surface,
preventing their release and thus infection of other cells.
Viruses have, however, developed means to counteract
this restriction factor. Viral protein U (Vpu) is an accessory
protein encoded by HIV-1, the causative agent of AIDS.
Vpu antagonizes Tetherin and consequently promotes the
release of HIV-1 particles. A series of recent reports
proposed that Vpu would induce the degradation of this
restriction factor in order to overcome its anti-viral activity.
Here, we report that Vpu is able to enhance HIV-1 release
in absence of Tetherin degradation. Instead, we found that
Vpu interacts with Tetherin and interferes with the
transport of the restriction factor towards the cell-surface.
This would lead to re-localization of Tetherin in an
intracellular organelle called the trans-Golgi network,
resulting in insufficient levels of Tetherin at the cell-surface
to trap progeny viruses. This mechanism of antagonism
that results in TGN trapping could be augmented by the
induction of degradation to effectively counteract the
powerful restrictive effects of human Tetherin. Further
characterization of this mechanism will improve our
understanding of host antiviral defenses as well as provide
new targets for the development of novel anti-HIV drugs.
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ectopic expression of HA-Tetherin strongly inhibited the release of
Vpu-defective HIV-1 particle relative to the Tetherin-negative
control as demonstrated by the drastic reduction of virion-
associated p24 in the supernatant (Fig. 1A, compare lanes 3 and
5 with lane 1; quantified in Fig. 1B). Interestingly, although Vpu
did not affect the total levels of exogenous HA-Tetherin at low
concentration, it still promoted efficient release of HIV-1 particle
(Fig. 1A, compare lane 5 with lane 6; quantified in Fig. 1B). These
results suggest that Vpu can reduce the total levels of Tetherin, yet
this process does not appear to be absolutely necessary to promote
HIV-1 particle release.
To further confirm these observations, we analyzed the turnover
of exogenously-expressed native Tetherin in condition of efficient
Vpu-mediated virus particle release by pulse-chase labeling
analysis (Fig. 2A-C). HEK 293T cells were co-transfected with
the proviral constructs HxBH10-vpu- or HxBH10-vpu+ and with a
plasmid encoding native Tetherin. Forty-eight hours post-
transfection, cells were pulse-labeled, chased for different intervals
of time and analyzed for Tetherin and Vpu expression levels by
sequential immunoprecipitation using specific antibodies (Abs). In
parallel, transfected cells as well as virus-containing supernatants
were collected prior to radio-labeling to monitor HIV-1 particle
release by western blot. Tetherin-specific bands ranging from ,20
kDa to ,29 kDa and likely representing putative glycosylated
forms of monomeric Tetherin were immunoprecipitated (Fig. 2A).
Ectopic Tetherin turnover was not altered by Vpu since none of
the Tetherin-specific bands showed any significant accelerated
reduction over time in the presence of the viral protein (Fig. 2A;
compare lanes 7–10 with lanes 3–6). Quantitative analysis of
Tetherin turnover revealed that exogenous Tetherin has a half-life
of approximately 3.5 h regardless of the presence of Vpu (Fig. 2B).
Importantly, this lack of effect of Vpu on Tetherin turnover was
observed in conditions of efficient Vpu-mediated HIV-1 particle
release (Fig. 2C).
We further evaluated the half-life of endogenous Tetherin in
infected HeLa cells in the presence or absence of Vpu. Vesicular
stomatitis virus glycoprotein G (VSV-G)-pseudotyped HxBH10-
vpu- or HxBH10-vpu+ virus-infected HeLa cells were pulse-labeled,
chased for different intervals of time and analyzed for Tetherin
expression levels as described above. In this system, endogenous
mature Tetherin was detected as a ,30–37 kDa smear (Fig. 2D).
A lower ,27 kDa band, distinct from the predicted Mr of 20 kDa
for unglycosylated Tetherin, was also detected at time 0 and most
probably corresponds to immature glycosylated forms of newly
synthesized Tetherin still residing in the ER. Exogenously- and
endogenously-expressed Tetherin were recently reported to
display distinct mobilities (,20–29 kDa (Fig. 2A) vs ,27 and
Figure 1. Enhancement of viral particle release in absence of Vpu-dependent reduction of Tetherin steady-state levels. HEK 293T
cells were co-transfected with a fixed amount of the HA-Tetherin-expressing plasmid (235 ng) and the indicated amounts of HxBH10 proviral
constructs. Forty-eight hours post-transfection, cells and virus-containing supernatants were harvested and processed for western blot analysis. (A)
Proteins in the viral and cell lysates were detected using specific Abs. (B) Quantification of HIV-1 release efficiency. Bands corresponding to Gag
products in cells and viral particles in panel (A), as detected using anti-p24 Abs, were scanned by laser densitometry. The virus particle release
efficiency was determined as described in the Materials and Methods and calculated as a percentage of the release of HxBH10-vpu+ (100%) in
absence of HA-Tetherin. The values within the graph represent the fold increase of virus particle release upon Vpu expression.
doi:10.1371/journal.ppat.1000856.g001
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carbohydrate modifications [36]. Indeed, as demonstrated by
Andrew and colleagues, we found that treatment of exogenous and
endogenous Tetherin with Peptide: N-Glycosidase F (PNGase), an
enzyme that cleaves all N-linked oligosaccharides, resulted in both
cases in deglycosylated Tetherin proteins with a Mr of 19–20 kDa
that were recognized by our anti-Tetherin serum (data not shown).
Figure 2D reveals that mature endogenous Tetherin has a half-
life (tK) of approximatively 8h (Fig. 2D, lanes 1–5; quantified in
Fig. 2E), which is indeed longer than exogenously-expressed
Tetherin (tK: 3.5 h). Tetherin turnover was accelerated in
presence of Vpu (tK: 3.5 h) (compare lanes 6–10 to lanes 1–5;
quantified in Fig. 2E), consistent with recent results reported by
Douglas and colleagues using HeLa cells transduced with Vpu-
expressing adenoviral vectors [20]. Since Vpu-mediated Tetherin
degradation was reported to rely on its capacity to recruit b-TrCP
[12,20,34,35], we evaluated the turnover of the restriction factor in
presence of the b-TrCP-binding defective Vpu S52D,S56D
mutant. This mutant harbors mutations at the key amino-acids
required for interaction with b-TrCP (Ser52, and Ser56 for Asp)
Figure 2. Analysis of the turnover of endogenous and exogenously-expressed Tetherin in the presence of Vpu. (A-C) Turnover of
exogenously-expressed Tetherin. (A) HEK 293T cells were co-transfected with the indicated HxBH10 proviral constructs and the pcDNA-Tetherin
plasmid. Forty-eight hours post-transfection, cells were pulse-labeled and chased for the indicated time intervals. Tetherin and Vpu were
immunoprecipitated with specific Abs, and analyzed by autoradiography. The asterisk indicates the presence of a non-specific signal. (B) Quantitation
of (A). The graph represents the percentage of Tetherin recovered relative to time 0. The signal intensity of all Tetherin-specific bands was determined
for each time point by densitometric scanning. The percentage of Tetherin recovered was calculated as the ratio of the Tetherin bands signal at a
given time relative to the signal at time 0. Error bars indicate the standard deviation of the mean from 2 independent experiments. (C) Virus-
containing supernatants and a fraction of the cells from (A) were collected prior to labeling. Gag proteins from the cell and viral lysates were analyzed
by western blot using anti-p24 Abs. (D-E) Turnover of endogenous Tetherin. (D) HeLa cells were infected with the indicated VSV-G-pseudotyped
HxBH10 virus. Forty-eight hours post-infection, cells were pulse-labeled and chased for the indicated time intervals. Tetherin was immunoprecipitated
with specific Abs, and analyzed by autoradiography. Vpu and actin were detected by western blot from cell lysates harvested prior to labeling. (E)
Quantitation of (D) as described in (B). Full black line: HxBH10-vpu+; Dashed line: HxBH10-vpu-; Full grey line: HxBH10-vpu S52D,S56D.
doi:10.1371/journal.ppat.1000856.g002
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Vpu S52N,S56N mutant [3,12,20,27,33,35,37,38]. Notably, Vpu
S52D,S56D is unable to mediate CD4 degradation [25] and to
recruit b-TrCP (Fig. S1A), but is however able to partially down-
regulate Tetherin from the cell-surface (Fig. S1B) and to promote
HIV-1 particle release, albeit to a different extent than WT Vpu
(Fig. S1C-D). Interestingly, even though Vpu S52D,S56D was still
capable of promoting HIV-1 particle release, its expression did not
affect Tetherin turnover (Fig. 2D, compare lanes 11–15 and lanes
1–5; quantified in Fig. 2E), consistent with the reported role of b-
TrCP in Vpu-mediated Tetherin degradation [12,20,34,35].
Taken together, these results provide evidence that Vpu can
promote HIV-1 particle release without a detectable reduction of
Tetherin intracellular levels or a notable modification of its
turnover, suggesting that reduction of total levels of Tetherin by a
degradative process may not be necessary and/or sufficient to fully
explain the anti-Tetherin activity of Vpu.
Vpu does not promote Tetherin endocytosis
Rodent Tetherin is internalized from the plasma membrane and
delivered back to the TGN through a clathrin-dependent pathway
that requires the sequential action of AP2 and AP1 adaptor
complexes [5]. Importantly, internalization was found to be
dependent upon a dual tyrosine (Tyr)-based motif (YXXW, where
Y corresponds to Tyr, the Xs are residues that are highly variable,
and W corresponds to residues with bulky side chains) in the N-
terminal cytoplasmic tail (amino acids at position 6 and 8) of the
protein (Fig. 3A). One alternative mechanism to explain how Vpu
down-regulates Tetherin cell-surface expression and counteracts
its antiviral activity is by enhancing the rate of Tetherin
endocytosis. To evaluate whether the natural pathway of Tetherin
endocytosis was necessary for the anti-Tetherin activity of Vpu, we
generated a mutant of Tetherin that harbored alanine substitu-
tions at the two key Tyr residues within the dual Tyr-based
internalization motif of the protein (HA-Tetherin Y6Y8) (Fig. 3A).
Consistent with the previously reported role of this Tyr-based
motif in rodent Tetherin endocytosis, substitution mutation of
Tyr6 and Tyr8 prevented HA-Tetherin from being efficiently
internalized from the cell-surface (Fig. 3B). To assess whether
mutation of the Tyr-based motif affected Tetherin sensitivity to
Vpu, HEK 293T cells were co-transfected with HxBH10-vpu-o r
HxBH10-vpu+ proviral constructs and plasmids encoding for HA-
Tetherin or HA-Tetherin Y6Y8. Even though HA-Tetherin Y6Y8
was expressed at higher levels at the cell-surface (mean
fluorescence intensity (MFI)=240) as compared to HA-Tetherin
wt (MFI=90), both proteins were down-regulated from the cell-
surface by Vpu and indeed appeared to reach similar cell-surface
steady state levels (MFI of 51 and 41, respectively) (Fig. 3C). HIV-
1 particle release was also monitored by western blot, 48h post-
transfection. Consistent with its higher cell-surface expression
levels, the restriction of virus particle release was more pronounced
in presence of HA-Tetherin Y6Y8 than with HA-Tetherin wt
(Fig. 3D; compare lanes 5 and 3 with lane 1; quantified in Fig. 3D).
It is interesting to note that the mutant protein was overall
expressed at higher levels than the WT protein (Fig. 3D, compare
lanes 5 and 3). This is likely the result of the inefficient clearance of
HA-Tetherin Y6Y8, which is not efficiently internalized from the
cell-surface. Nevertheless, Vpu was still proficient at overcoming
the restricting activity of HA-Tetherin Y6Y8 on HIV-1 particle
release as demonstrated by the increased levels of virion-associated
p24 released in the supernatant (Fig. 3D, compare lane 6 with lane
5; quantified in Fig. 3E). Similarly, a 2h treatment with 10 mM
chlorpromazine, a drug that blocks clathrin-coated pit assembly at
the plasma membrane [39], did not affect the ability of Vpu to
overcome Tetherin-mediated restriction of HIV-1 particle release
in HeLa cells (data not shown). Altogether, these results suggest
that Vpu does not manipulate clathrin-mediated endocytosis, the
natural pathway of Tetherin endocytosis, as a mean to deplete the
restriction factor from the cell-surface or to antagonize its antiviral
activity.
Since Vpu could accelerate Tetherin endocytosis by a clathrin-
independent process, we next asked whether Vpu affected
Tetherin internalization kinetics from the cell-surface using an
assay that measures the contribution of all endocytosis pathways.
To this end, we compared the rate of endocytosis of endogenous
Tetherin in HeLa cells that were producing Vpu-positive HIV-1
(HxBH10-vpu+) with those producing a Vpu-defective virus
(HxBH10-vpu-) (Fig. 4). Consistent with previous studies of rodent
Tetherin [5], human Tetherin was internalized constitutively.
Interestingly, even though Vpu down-regulated Tetherin expres-
sion on the cell-surface (data not shown), the internalization
kinetics of cell-surface Tetherin was unaffected (Fig. 4). These
results indicate that Vpu does not counteract Tetherin restriction
by promoting Tetherin endocytosis.
Vpu interferes with Tetherin trafficking to the cell-surface
We have recently reported that regulation of HIV-1 release
correlates with co-localization of Vpu and Tetherin in the TGN,
thus raising the possibility that Vpu could act intracellularly by
affecting Tetherin trafficking [40]. A cell-surface Tetherin re-
expression assay was developed to determine whether Vpu affects
Tetherin trafficking to the cell-surface. Conceptually, this assay
implies the loss of Tetherin epitopes at the cell-surface and their
subsequent recovery over time as demonstrated previously for
analysis of the Mtv-1 Superantigen protein trafficking [41]. HeLa
cells were co-transfected with the HxBH10-vpu- or HxBH10-vpu+
proviral constructs as well as with a GFP-encoding plasmid to
allow gating of transfected cells. Forty-eight hours post-transfec-
tion, cells were harvested and treated with pronase (0.05%) to
proteolytically remove cell-surface protein epitopes. After quench-
ing the proteolytic reaction, stripped cells were incubated at 37uC
for different time intervals to allow protein intracellular trafficking
and re-expression at the cell-surface and then stained at 4uC with
anti-Tetherin Abs. Expression of Tetherin in transfected (GFP-
positive) or untransfected (GFP-negative) subpopulations was
analyzed by flow cytometry (Fig. 5). As expected, dot plots
revealed that Tetherin levels were down-regulated by Vpu in the
untreated cells (compare the GFP-positive/HxBH10-vpu+ subpop-
ulation MFI (MFI=36.8) with those of the GFP-negative/
HxBH10-vpu+ (MFI=56.7) or GFP-positive/HxBH10-vpu-
(MFI=61.0) subpopulations) (Fig. 5A, untreated). Pronase treat-
ment markedly reduced the levels of Tetherin at the cell-surface,
indicating that Tetherin epitopes were efficiently removed from
the cell-surface. Interestingly, the levels of Tetherin detected at
time 0 in the GFP-positive/HxBH10-vpu+ subpopulation was still
lower (MFI=6.7) than those detected in the GFP-negative/
HxBH10-vpu+ (MFI=9.7) or GFP-positive/HxBH10-vpu-
(MFI=12.7) subpopulations (Fig. 5A, time 0 min). Similar levels
of Tetherin re-expression was detected at the cell-surface of GFP-
positive/HxBH10-vpu- cells and GFP-negative cells after 180 min
of incubation as demonstrated by the comparable MFI detected in
the two subpopulations. In contrast, Vpu caused a substantial
reduction in Tetherin re-expression after 180 min, as shown by
the lower MFI value in the GFP-positive/HxBH10-vpu+ popula-
tion (MFI=19) compared to GFP-negative/HxBH10-vpu+ cells
(MFI=38.1) (Fig. 5A; 180 min). Treatment of cells with 10 mM
Brefeldin A (BFA), a fungal metabolite that blocks protein sorting
from the ER to the Golgi, prevented efficient Tetherin re-
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and untransfected (GFP-negative) cells, demonstrating the speci-
ficity of the re-expression assay (Fig. 5A, BFA). It is interesting to
note that the absolute difference (D) in MFI detected between the
Vpu-expressing cells and control cells (GFP-positive or negative/
HxBH10-vpu- and GFP-negative/HxBH10-vpu+) was amplified
after 180 min (D=,19) as compared to time 0 (D=,3–6),
suggesting an effect of Vpu on cell-surface Tetherin re-expression
kinetics. Indeed, the kinetics of Tetherin re-expression at the cell-
surface, as measured by evaluating Tetherin levels (MFI) at the
surface of pronase-treated cells relative to the corresponding
untreated GFP-negative control over 180 min, increased linearly
in the GFP-positive/HxBH10-vpu- and was indistinguishable from
that of the GFP-negative/HxBH10-vpu+ control (slope of 0.27–
0.29; Fig. 5B). After 180 min, approximately 75% of cell-surface
Tetherin was recovered in both cases. In contrast, in presence of
Vpu only ,35% of Tetherin expression was recovered at the cell-
surface. Indeed, the kinetics of Tetherin re-expression in these
Vpu-expressing cells was much slower than the controls (slope of
,0.14; Fig. 5B). Interestingly, the kinetics of Tetherin re-
expression was similarly delayed in presence of the Vpu
S52D,S56D mutant (slope of ,0.11), indicating that the observed
effect of Vpu on Tetherin re-expression at the cell-surface is not
the consequence of Tetherin degradation. Similar analysis based
on the proportion of Tetherin-positive cells as a read-out (cut-off
was arbitrarily set on the pronase-treated HxBH10-vpu+/GFP+
time 0 sample) revealed analogous results (data not shown). Thus,
our results suggest that Vpu expression interferes with Tetherin
trafficking along the secretory and/or recycling pathways.
Vpu expression causes a re-localization of the cellular
pool of Tetherin in a perinuclear compartment
To further support these observations and identify the
intracellular compartment where Tetherin might accumulate in
presence of Vpu, we analyzed the intracellular distribution of
endogenous Tetherin in VSV-G-pseudotyped HxBH10-vpu- and
HxBH10-vpu+ virus-infected HeLa cells by immunostaining and
confocal microscopy. To this end, we developed a staining
protocol, which allowed simultaneous detection of Tetherin at
the cell-surface and in intracellular compartments as described in
the Materials and Methods. In the absence of Vpu, Tetherin was
detected primarily at the plasma membrane but also to a lower
extent on internal membranes that overlapped partially with
TGN46, a cellular marker of the TGN (Fig. 6, Vpu- panels),
consistent with previous intracellular localization studies of rodent
Tetherin [4,13]. This localization pattern was drastically altered
by the presence of Vpu, which caused an effective removal of
Tetherin from the cell-surface without, however, significantly
affecting the pool of proteins localized in the perinuclear
compartment that co-stained with TGN46 (Fig. 6A, Vpu+ panels
and Fig. 6B). Notably, as reported previously by our laboratory
[40], Vpu and Tetherin co-localized extensively in the TGN. This
altered localization pattern of Tetherin was not observed in
neighbouring untransfected cells, which indeed displayed a strong
Tetherin staining at the plasma membrane. Since we found that
Vpu was accelerating Tetherin turnover in HeLa cells in a b-
TrCP-dependent manner (Fig. 2D), we next analyzed the
distribution of Tetherin in presence of the Vpu S52D,S56D
mutant. In contrast to infected HeLa cells expressing WT Vpu,
residual Tetherin was still readily detected at the plasma
membrane of infected cells expressing the Vpu S52D,S56D
mutant (Fig. 6A, Vpu S52D,S56D panels), a finding that most
probably reflects the fact that this mutant is less efficient at down-
regulating Tetherin from the cell-surface than WT Vpu (Fig. S1B).
Interestingly, expression of this mutant resulted in a re-localization
of the cellular pool of Tetherin in the TGN (Fig. 6A). Importantly,
Vpu S52D,S56D caused an ,4-fold increase of the absolute
staining signal of Tetherin in the TGN relative to WT Vpu or the
Vpu- control (Fig. 6B), suggesting that in absence of degradation,
Vpu traps Tetherin in the TGN. Taken together, these
microscopy studies suggest that HIV-1 Vpu promotes the
sequestration of endogenous Tetherin in the TGN, most probably
before triggering b-TrCP-dependent Tetherin degradation, thus
preventing Tetherin’s trafficking to the plasma membrane. Since
these localization studies were performed in HIV-1-infected cells,
these results further indicate that Tetherin sequestration occurs at
physiological levels of Vpu expression.
Association of Vpu and Tetherin involves their
transmembrane anchor domains
Having shown that Vpu expression affects the intracellular
trafficking of Tetherin to the cell-surface and promotes a
sequestration of Tetherin in the TGN, we next assessed whether
Vpu can associate with Tetherin. HEK 293T cells were co-
transfected with the HxBH10-vpu- or HxBH10-vpu+ proviral
constructs as well as with a plasmid encoding HA-tagged Tetherin.
Forty-eight hours post-transfection, cells were lysed in stringent
detergent conditions with RIPA-DOC lysis buffer to avoid
unspecific association resulting from membrane bridging. Tetherin
was then immunoprecipitated from cell lysates with anti-Tetherin
antibodies and the immunocomplexes were analyzed for the
presence of Vpu by western blot. Immunoprecipitation of HA-
Tetherin led to a selective pull-down of the Vpu protein,
suggesting that Vpu can directly or indirectly interact with
Figure 3. Mutation of Tetherin dual Tyrosine-based sorting motif does not affect sensitivity to Vpu. (A) Schematic representation of HA-
Tetherin wt and HA-Tetherin Y6Y8. The overlapping Tyr-based motifs are presented in the grey box. X and W correspond to variable and hydrophobic
amino-acid residues, respectively. Hyphens represent unchanged amino-acids. The site that is cleaved prior to addition of the GPI lipid anchor is
represented by the dashed line. Glycosylation sites are represented at position 65 and 92. (B) Kinetics of HA-Tetherin Y6Y8 internalization. HEK 293T
cells were co-transfected with the indicated HxBH10 constructs and a GFP-expressing plasmid. Forty-eight hours post-transfection, cell-surface
Tetherin was labeled with Tetherin specific Abs at 4uC before incubating cells at 37uC for the indicated time intervals to allow endocytosis. Cells were
then incubated at 4uC in presence of appropriate secondary Abs. The graph depicts the relative levels of Tetherin at the surface of GFP-expressing
cells (time 0=100%) and represents the loss of Tetherin-specific signal following endocytosis. (C) Cell-surface expression of HA-Tetherin Y6Y8. HEK
293T cells were co-transfected with the indicated HA-Tetherin plasmid and HxBH10 proviral constructs in presence of a GFP-expressing plasmid. Cell-
surface Tetherin expression was analyzed on GFP-positive cells by flow cytometry 48 h post-transfection. Geo mean values (depicted as MFI) are
shown. Full lines: HxBH10-vpu+; dashed lines: HxBH10-vpu-; filled histogram: pre-immune control. The results are representative of two independent
experiments. (D) Effect of HA-Tetherin Y6Y8 on HIV-1 particle release. HEK 293T cells were co-transfected with the indicated HxBH10 proviral
constructs and HA-Tetherin-expressing plasmids. Forty-eight hours post-transfection, transfected cells and virus-containing supernatants were
harvested. Proteins from cell and viral lysates were analyzed by western blot using specific Abs. (E) Quantitation of HIV-1 particle release. Bands
corresponding to Gag products in cells and viral particles were scanned by laser densitometry. The virus particle release efficiency was determined as
described in the Materials and Methods and calculated as a percentage of the release of HxBH10-vpu+ (100%) in absence of HA-Tetherin. Error bars
indicate the standard deviation of the mean from two independent experiments.
doi:10.1371/journal.ppat.1000856.g003
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(Fig. 7B, lane 8). Early studies aimed at mapping the regions of
Vpu necessary for enhancing HIV-1 release identified the TM
domain of the protein as an important functional determinant
since Vpu mutants that contained a randomized TM region (Vpu
RD) or harbored point mutations within the TM spanning
domain, such as Vpu KSL, failed to enhance virus particle release,
yet were still stable, properly localized in a perinuclear
compartment and able to induce efficient CD4 degradation
[42,43]. Vpu KSL contains a three amino-acid substitution in
which Ile6, Ile8, and Val9 were replaced by Lys, Ser, and Leu,
respectively, and contains a positively charged amino-acid in an
area that is devoid of charge. To evaluate whether Vpu interacted
with Tetherin through the TM anchor domain, we performed
similar co-immunoprecipitations in HEK293T cells co-transfected
with a plasmid encoding HA-tagged Tetherin and proviral
constructs encoding Vpu RD (HxBH10-vpu RD) or Vpu KSL
(HxBH10-vpu KSL) (Fig. 7A). In contrast to WT Vpu, both the
Vpu RD and Vpu KSL mutants failed to co-immunoprecipitate
efficiently with HA-Tetherin (Fig. 7B, compare lanes 9 and 10
with lane 8), suggesting that the association between the two
proteins involves the TM domain of Vpu.
Since the TM of Vpu represents an important determinant for
the association with Tetherin, we next determined whether the
TM domain of Tetherin was also involved. Tetherin TM was
recently proposed to contain the determinants responsible for the
species-specific sensitivity to Vpu [29,31,32]. Notably, reciprocal
exchange of TM domains between human (h) and rhesus monkey
Tetherin (THN) proteins conferred sensitivity and resistance to
Vpu and alterations in the human Tetherin TM domain that
correspond to differences found in rhesus and agm Tetherin
proteins were sufficient to render human Tetherin completely
resistant to HIV-1 Vpu [29,31,32]. We constructed a set of
expression plasmids encoding HA-tagged Tetherin chimeras with
reciprocal exchanges of the TM between the human and agm
proteins (Fig. S2A). In addition, we generated an expression
plasmid encoding a HA-tagged human Tetherin that harbors
double mutations in the TM domain (HA-human Tetherin
DGI,T45I) comprising a deletion of Gly25 and Ile26 residues
and a substitution of Thr45 for an Ile (Fig. S2A). This mutant was
previously reported to strongly inhibit HIV-1 particle release but
was completely resistant to antagonism by Vpu [29]. HEK 293T
cells were co-transfected with the HxBH10-vpu- or HxBH10-vpu+
proviral constructs as well as with the indicated HA-Tetherin-
encoding plasmids (Fig. 7C-E). Forty-eight hours post-transfection,
Tetherin was immunoprecipitated from cell lysates and immuno-
complexes were further analyzed for the presence of Vpu by
western blot. Since HA-agm Tetherin and the HA-
agmTHN(hTM) chimeras were less expressed and/or detected
using our anti-human Tetherin Abs (these chimeras were not
efficiently precipitated with anti-HA Abs), Vpu association was
compared between Tetherin variants displaying similar expression
profiles. As shown in Figure 7C, immunoprecipitation of HA-
human Tetherin co-precipitated Vpu (Fig. 7C, lane 12). As
expected, HA-agm Tetherin, which was reported to be resistant to
Vpu antagonism [29,32], did not show a strong and specific
association with Vpu. In contrast, replacement of the agm
Tetherin TM domain with that of human Tetherin (HA-
agmTHN(hTM)) restored the association with Vpu (Fig. 7C,
compare lane 14 with lanes 16 and 12). Exchange of the human
Tetherin TM with that of agm Tetherin (HA-hTHN(agmTM)) led
to a marked reduction of Vpu association despite comparable
levels of Tetherin expression (Fig. 7D, compare lane 12 with lane
10). Finally, introduction of the DGI,T45I mutations in the TM
domain of HA-human Tetherin drastically reduced the association
with Vpu (Fig. 7E, compare lane 12 with lane 10). These results
suggest that the integrity of the TM domain of human Tetherin is
necessary for the association with Vpu. Taken together, our data
suggests that association of Vpu and human Tetherin involves
their TM anchor domains.
Association of Vpu to Tetherin is required to down-
regulate the expression of the restriction factor at the
cell-surface and to promote HIV-1 particle release
We next assessed whether association of Vpu to Tetherin was
required to counteract Tetherin antiviral activity (Fig. 8). To do so,
we transfected a proviral construct encoding WT Vpu or the Vpu
KSL mutant in HeLa cells and first assessed their ability to
associate with endogenous Tetherin. Wild type Vpu co-precipi-
tated with endogenous Tetherin while Vpu KSL did not,
confirming the results obtained when exogenous HA-tagged
Tetherin was overexpressed in HEK293T cells expressing
HxBH10-vpu+ or HxBH10-vpu KSL proviruses (Fig. 8A, compare
lane 6 with lane 5). Association of Vpu with endogenous Tetherin
was specific since HIV-1 envelope glycoprotein precursor gp160,
another type 1 integral protein, did not co-precipitate with
Tetherin (Fig. 8A). Interestingly, the Vpu KSL mutant was
strongly attenuated in its ability to down-regulate the steady-state
levels of Tetherin at the cell-surface relative to WT Vpu since
Tetherin cell-surface expression in presence of Vpu KSL was
significantly higher than in presence of WT Vpu (MFI of 191 vs
138), yet still slightly lower than in the Vpu-negative control
(MFI= 235) (Fig. 8B). Importantly, as previously reported [43],
Figure 4. Vpu antagonizes Tetherin without promoting its
endocytosis. HeLa cells were co-transfected with the indicated
HxBH10 constructs and a GFP-expressing plasmid. Forty-eight hours
post-transfection, cell-surface Tetherin was labeled with Tetherin
specific Abs at 4uC before incubating cells at 37uC for the indicated
time intervals to allow endocytosis. Cells were then incubated at 4uCi n
presence of the appropriate secondary Abs. The graph depicts the
relative levels of Tetherin at the surface of GFP-expressing cells (time
0=100%) and represents the loss of Tetherin-specific signal resulting
from endocytosis. Full lines: HxBH10-vpu+; dashed lines: HxBH10-vpu-.
Error bars indicate the standard deviation of the mean from two
independent experiments.
doi:10.1371/journal.ppat.1000856.g004
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efficient HIV-1 particle release (Fig. 8C, compare lanes 3 and 2
with lane 1; quantified in Fig. 8D). Similarly to Vpu KSL, the Vpu
RD mutant, which is also defective for Tetherin binding, was also
markedly attenuated in its ability to down-regulate Tetherin cell-
surface expression and to promote efficient HIV-1 release in HEK
293T cells ectopically-expressing Tetherin (Fig. S3A and B),
consistent with results reported by previous studies [3,42]. Human
Tetherin containing the agm TM domain (HA-hTHN(agmTM))
or the DGI,T45I mutations (HA-human Tetherin DGI,T45I) lost
the ability to bind Vpu (Fig. 7D and E) and as expected still
restricted HIV-1 particle release even in the presence of Vpu (Fig.
S2B and C for HA-hTHN(agmTM) and Fig. S2D and E for HA-
human Tetherin DGI,T45I). Unexpectedly, introduction of the
human Tetherin TM domain in agm Tetherin (HA-
agmTHN(hTM), did not reinstate a significant sensitivity to Vpu
(Fig. S2 B and C), despite a detectable restoration of the Vpu
binding (Fig. 7C). This functional phenotype (absence of Vpu
sensitivity) is different from that obtained by McNatt and
colleagues [29] using agm or rhesus Tetherins containing the
human Tetherin TM domain but is similar to that reported by
Goffinet and colleagues [30] using rodent Tetherin proteins
containing the human Tetherin TM domain. Difference in the
configuration of the TM domain in these Tetherin chimeric
constructs may explain this discrepancy. The result obtained with
the HA-agmTHN(hTM) chimeric construct suggests that associ-
ation of Tetherin with Vpu is necessary but not sufficient to
overcome Tetherin-mediated restriction of HIV-1 particle release.
However, we cannot rule-out the possibility that the binding of
Vpu to the HA-agmTHN(hTM) chimeric protein may indeed be
less efficient than with HA-human Tetherin since our antibody
may underestimate the levels of expressed HA-agmTHN(hTM)
proteins (Fig. 7C, compare lane 14 and lane 12). Thus,
alternatively, a threshold level of Vpu association to Tetherin
may be necessary to antagonize the antiviral activity of the
restriction factor. Nonetheless, overall, these results suggest that
association of Vpu to Tetherin is required to antagonize the
antiviral function of the restriction factor.
Figure 5. Vpu affects Tetherin trafficking to the cell surface.
(A-B) HeLa cells were transfected with the indicated HxBH10 proviral
constructs and a GFP-expressing plasmid. Forty-eight hours post-
transfection, cells were harvested and treated with pronase (0.05%).
After quenching of the proteolytic reaction, cells were cultured at
37uC for different time intervals and then immunostained for cell-
surface Tetherin. (A) Dot plots representing cell-surface Tetherin levels
relative to GFP expression. MFI values are presented for each gate.
Treatment with BFA (10 mM) served as a positive control for
intracellular retention. BFA was added to the media immediately
after treatment with pronase and kept throughout the chase period.
(B) Quantitative representation of panel (A). Kinetics of Tetherin re-
expression were determined by calculating the percentage of
Tetherin expression (MFI) at the surface of pronase-treated cells
relative to the corresponding untreated GFP-negative control at
different time intervals. Equations pertaining to each linear equation
are shown above the graph. Error bars represent the standard
deviation of at least two separate experiments. Black dashed line:
HxBH10-vpu+/GFP-; black full line: HxBH10-vpu-/GFP+;r e df u l ll i n e :
HxBH10-vpu+/GFP+;b l u ef u l ll i n e :H x B H 1 0 - vpu S52D,S56D/GFP+.
Similar results were obtained when the proportion of cells expressing
Tetherin at the cell-surface was used as a read-out instead of Tetherin
MFI. For these latter analyses, the cut-off was arbitrarily set on the
pronase-treated HxBH10-vpu+/GFP+ time 0 sample (illustrated by the
dotted line in Figure 5A) so that the background level of Tetherin-
positive cells corresponded to 1%.
doi:10.1371/journal.ppat.1000856.g005
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infected with VSV-G pseudotyped HxBH10-vpu-, HxBH10-vpu+ or HxBH10-vpu S52D,S56D virus. Forty-eight hours post-infection, cells were
immunostained for cell-surface Tetherin, fixed, permeabilized and co-stained with anti-Tetherin (red), anti-Vpu (green) and anti-TGN46 (blue) specific
Abs. Nuclei were counterstained with DAPI (cyan). Cells were observed by confocal microscopy. The white scale bar represents a distance of 10 mm.
(B) Quantitation of the absolute Tetherin signal in the TGN was determined by measuring the specific Tetherin signal in the region delineated by the
TGN46 marker on digital picture produced using similar acquisition time. Error bars indicate the standard deviation of the mean from the quantitative
analysis of at least 25 distinct cells per conditions.
doi:10.1371/journal.ppat.1000856.g006
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localization of the restriction factor in the TGN
Since we showed that expression of Vpu could cause a re-
localization of Tetherin from the plasma membrane to the TGN,
we next tested whether the Vpu TM domain mutants, Vpu RD
and Vpu KSL, which are unable to associate with Tetherin, could
still sequester endogenous Tetherin in the TGN. Hela cells were
infected with VSV-G-pseudotyped viruses expressing WT Vpu or
Vpu RD or Vpu KSL and infected cells were immunostained and
analyzed by confocal microscopy. Figure 9 reveals that both the
Vpu RD and Vpu KSL lost the ability to efficiently remove
Tetherin from the cell-surface and to relocate the restriction factor
to the TGN. Indeed, quantitative analysis of the Tetherin signal
localized in the TGN relative to the total cellular Tetherin signal
showed that cells expressing the Tetherin degradation-defective
Vpu S52D,S56D mutant displayed an increased proportion of
Tetherin signal in the TGN compared to the Vpu- control. (,57%
relative to ,18%; p,0.001) (Fig. 6). In contrast, cells expressing
the Vpu RD or Vpu KSL mutants showed ,25% of the Tetherin
signal in the TGN, a proportion that was in fact just slightly higher
than that found in cells infected with a Vpu-defective virus (Fig. 9).
Accordingly, in contrast to Vpu S52D,S56D, these mutants did
not show any increase in the absolute levels of Tetherin signal in
the TGN (Fig. 9). These results indicate that Vpu promotes the
sequestration of Tetherin in the TGN by a process that is
dependent on the association of the two proteins. Taken together
with the functional analysis and the co-precipitation experiments,
these results further suggest that the antagonism of Tetherin
function by Vpu involves binding and sequestration of the
restriction factor in the TGN.
Discussion
The Vpu accessory protein stimulates the release of HIV-1
virions by antagonizing a restriction on virus particle release
mediated by Tetherin at the cell-surface [2,3]. This antagonism
appears to closely correlate with the ability of Vpu to mediate
down-regulation of Tetherin expression from the cell-surface
[3,12,20]. While this down-regulation is accompanied by en-
hanced degradation of Tetherin in several infected cell types, such
as Jurkat [20] and CEM-G37 T cells [21] or macrophages [33],
several lines of evidence also suggest that degradation of Tetherin
per se cannot entirely account for Vpu-mediated counteraction of
the restriction factor since: 1) Vpu decreased total cellular
Tetherin to a lesser extent than cell-surface Tetherin in HeLa
cells [12]; 2) Vpu expression did not result in a reduction of
intracellular Tetherin in infected CEMx174 and H9 cells, yet virus
replication in these cells was Vpu-responsive [33]; 3) Vpu mutants
that contained substitution mutation in the DSGWXS b-TrCP
recognition motif that rendered them deficient for directing b-
TrCP-dependent degradation of Tetherin were still able to
partially [3,12,20,34,37] (Fig. S1C and D) or in some instances
totally [33,44] overcome the particle release restriction; 4) binding
of Vpu to Tetherin was recently shown to be sufficient for a partial
relief of the restriction [20,34].
We show here that Vpu can promote efficient HIV-1 particle
release without a detectable reduction of the total steady-state
levels of Tetherin (Fig. 1) nor a notable modification of the
restriction factor turnover rate in transfected HEK 293T cells
(Fig. 2A -C), suggesting that degradation of the antiviral factor per
se is not necessary and/or sufficient to account for Tetherin
antagonism at least in this experimental system. Interestingly, Vpu
expression in HeLa cells increased endogenous Tetherin turnover
(Fig. 2D and E), as reported previously by Douglas and colleagues
[20]. This Vpu-mediated degradation process was however still
relatively slow (half-life of Tetherin decreases from ,8 h to 3.5 h
in presence of Vpu) as compared to the very efficient CD4
receptor degradation induced by Vpu (half-life of CD4 decreases
from ,6ht o,12 min in presence of Vpu) [45], and as such is
unlikely to explain the powerful antagonism of Tetherin by Vpu.
Thus, Vpu-mediated counteraction of Tetherin restriction must
involve other mechanisms. Our results further indicate that Vpu
does not promote endocytosis of Tetherin as a mechanism to
antagonize the restriction factor. Indeed, mutation of the two
critical tyrosine residues located within a dual tyrosine-based
sorting motif in the cytoplasmic domain of the protein, did not
abolish the sensitivity of Tetherin to Vpu, as was indeed recently
reported by Iwabu and colleagues [35], yet led to an increased
accumulation of the restriction factor at the cell-surface and to a
more potent restriction of HIV-1 particle release (Fig. 3).
Moreover, although analysis of Tetherin endocytosis kinetics
showed that the protein is constitutively internalized, it did not
reveal any increase in the rate of Tetherin endocytosis in presence
of Vpu (Fig. 4), and as such confirmed the results recently reported
by Mitchell and colleagues [12]. These results are consistent with
previous findings showing that Vpu-mediated enhancement of
virus particle release is not significantly affected by expression of
dominant negative (DN) mutants of Dynamin or Rab5 nor by
depletion of clathrin heavy chain or by treatment with inhibitors of
endocytosis such as chlorpromazine (data not shown) [6,40,46].
Collectively, they indicate that Vpu does not antagonize Tetherin
by enhancing its endocytosis from the cell-surface. Instead, these
findings suggest that Vpu affects Tetherin anterograde trafficking
events whose net effect is depletion of the restriction factor from
the cell-surface. In support of this hypothesis, a previous report
suggested that Vpu may acts as a regulator of protein transport
along the secretory pathway [47]. In fact, upon analyzing the
kinetics of Tetherin expression at the cell-surface of protease-
treated HeLa cells, we noticed that Tetherin re-expression was
significantly reduced in presence of Vpu (Fig. 5). It is important to
note, here, that this effect is occurring regardless of whether Vpu is
inducing Tetherin degradation in these experimental conditions
since: 1) it is the rate of re-expression, as defined by the slope of the
graph of Figure 5B that is affected in presence of Vpu; 2) re-
expression of cell-surface Tetherin was also delayed in presence of
the Tetherin degradation-defective Vpu S52D,S56D mutant
Figure 7. Association of Vpu and Tetherin involves their transmembrane anchor domains. (A) Schematic representation of WT Vpu, Vpu
KSL and Vpu RD. The TM domain is represented by the unfilled box while the cytosolic domain with the two predicted a-helices (H-1 and H-2) is
indicated by the filled box. Phosphorylation sites are represented by the small circles. The amino-acid sequence of the TM anchor region is
represented below. Hyphens represent identical amino-acids. (B-E) Co-immunoprecipitation experiments of Tetherin and Vpu. (B) HEK 293T cells were
transfected with a HA-human Tetherin-expressing plasmid and the indicated HxBH10-derived proviral constructs. Forty-eight hours post-transfection,
cells were lysed and proteins were co-immunoprecipitated using anti-Tetherin Abs. Co-immunoprecipitated proteins were analyzed by western blot
using anti-Tetherin and anti-Vpu Abs. (C-E) HEK 293T cells were transfected with the indicated HA-Tetherin-expressing plasmids and the specified
HxBH10 proviral constructs. Forty-eight hours post-transfection, cells were lysed and proteins were co-immunoprecipitated and analyzed as
described above. In (D), HA-Tetherin proteins were revealed by western blot using anti-HA Abs. Amounts of protein in the lysates prior to
immunoprecipitation (input) are shown in the left panels. Non-specific bands, depicted by the asterisks, were used as loading controls.
doi:10.1371/journal.ppat.1000856.g007
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HeLa cells expressing Vpu revealed that the cellular pool of
Tetherin was re-localized from the cell-surface to a perinuclear
compartment that stained positive with the TGN marker TGN46
and Vpu itself (Fig. 6). Although some of the loss of cell-surface
Tetherin in Vpu-expressing HeLa cells could be attributed to Vpu-
mediated degradation of the restriction factor, similar experiments
performed with the Vpu S52D,S56D mutant demonstrated that
Vpu can cause a redistribution of Tetherin from the plasma
membrane to the TGN. These results suggest that reduction of
Tetherin levels at the plasma membrane involves a step whereby
Vpu sequesters Tetherin in the TGN. They also provide a possible
mechanism to explain the partial relief of Tetherin restriction
observed by several groups upon expression of b-TrCP-binding
Figure 8. Association of Vpu to Tetherin is required to antagonize the antiviral activity of the restriction factor. (A) Association of Vpu
with endogenous Tetherin. HeLa cells were transfected with the indicated HxBH10 proviral constructs. Forty-eight hours post-transfection, cells were
lysed and proteins were co-immunoprecipitated using anti-Tetherin Abs. Co-immunoprecipitated proteins were analyzed by western blot using anti-
Tetherin, anti-Vpu and anti-Env Abs. The amount of proteins in the lysate prior to immunoprecipitation (input) is shown in the left panel. Non-specific
bands, depicted by the asterisks, were used as loading controls. (B) Cell-surface expression of Tetherin. HeLa cells were transfected with the indicated
HxBH10 proviral constructs and a GFP-expressing plasmid. Cell-surface Tetherin expression was analyzed on GFP-positive cells by flow cytometry, 48h
post-transfection. MFI values are shown beside the histogram. Filled histogram: pre-immune control; dashed line: HxBH10-vpu-; full line: HxBH10-
vpu+; dotted line: HxBH10-vpu KSL. (C) Effect of Vpu on HIV-1 particle release. Cells and virus-containing supernatants were collected from the
experiment described in (A), lysed and analyzed for the detection of Gag-related products by western blot using specific Abs. (D) Quantitation of virus
particle release. Bands corresponding to Gag products in cells and virus particles were scanned by laser densitometry. The virus particle release
efficiency was determined as described in the Materials and Methods and calculated as a percentage of the HxBH10-vpu+ virus release (100%). The
error bars represent the standard deviation from the mean of three independent experiments.
doi:10.1371/journal.ppat.1000856.g008
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Tetherin was still readily detected at the plasma membrane of
HeLa cells expressing the Vpu S52D,S56D mutant (Fig. 6A and
Fig. S1B), this sequestration may not be sufficient to effectively
prevent Tetherin to reach the cell-surface at least in this model.
These observations underline, perhaps, the need for b-TrCP-
mediated trafficking and degradation processes as a complemen-
tary mechanism to efficiently remove Tetherin from the cell-
surface, particularly in certain cell types or under specific
conditions, such as IFN exposure, where cellular Tetherin
expression levels are high. Thus, the different particle release
phenotypes observed with Vpu mutants that are unable to recruit
b-TrCP, such as Vpu S52D,S56D, (these range from as efficient
than WT Vpu to a ,50% attenuation) [3,12,20,33,34,37,44] may
in fact relate to differing levels of Tetherin expression in the target
cells. Although, it is conceivable that Vpu-mediated sequestration
of Tetherin in the TGN may explain how Vpu antagonizes
Tetherin in the absence of a decrease in total Tetherin expression,
it still remains unclear how Vpu could antagonize Tetherin in the
absence of down-regulation from the cell-surface and a decrease in
total cellular expression in certain cell types [33].
We also confirmed by co-immunoprecipitation studies that Vpu
interacts with Tetherin [20,32,34,35] and demonstrated using
well-characterized Vpu and Tetherin mutants as well as chimeric
proteins between human and African green monkey Tetherin
molecules that this physical interaction involves the transmem-
brane domains of the two proteins (Fig. 7 and Fig. 8). These
findings are consistent with previous results showing that the
transmembrane domain of Vpu is required for both the down-
regulation of surface Tetherin and the enhancement of HIV-1
particle release [3,42,43]. They are also supported by recent data
indicating that the inability of Vpu to antagonize the restrictive
effect of African green monkey and rhesus Tetherin proteins is a
consequence of amino-acid changes in the transmembrane
domain of the rhesus and African green monkey protein relative
to the human form [29,32]. Importantly, our data establish a
direct functional link between association of Vpu to Tetherin and
Tetherin antagonism since we showed that Vpu’s ability to interact
with Tetherin was necessary: 1) to counteract the restriction on
HIV-1 particle release and down-regulate Tetherin from the cell-
surface (Fig. 8, Fig. S2 and S3); and, 2) to induce a re-localization
of the cellular pool of Tetherin from the plasma membrane to the
TGN (Fig. 9). Unexpectedly, our observation showing that
introduction of the human Tetherin TM domain in African green
monkey Tetherin did not reinstate a significant sensitivity to Vpu
(Fig. S2B and C) despite a detectable restoration of the Vpu
binding raises the possibility that this interaction may not be
sufficient to explain Tetherin antagonism. The requirement for
additional cellular factor(s) in the Vpu-mediated Tetherin
antagonism is therefore a possibility that warrants further
investigations.
Since our co-immunoprecipitation and functional data indicate
that a physical interaction between Vpu and Tetherin is required
for Tetherin antagonism and sequestration, this raise the
possibility that Vpu may simply interact with Tetherin and inhibit
its outward trafficking from the TGN since all membrane proteins
are transported to the plasma membrane through the TGN
(Fig. 10). Since mutation of the dual Tyr signal in the Tetherin
Figure 9. Re-localization of Tetherin in the TGN requires the association of Vpu to the restriction factor. HeLa cells were infected with
the indicated VSV-G pseudotyped HxBH10-derived virus. Forty-eight hours post-infection, cells were immunostained for cell-surface Tetherin, fixed,
permeabilized and co-stained with anti-Tetherin (red), anti-Vpu (green) and anti-TGN46 (blue) specific Abs. Nuclei were counterstained with DAPI
(cyan). Cells were observed by confocal microscopy. The white bar represents a distance of 10 mm.
doi:10.1371/journal.ppat.1000856.g009
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that Tetherin sequestration in the TGN may occur before its
endocytosis from the cell-surface and as such may involve newly
synthesized Tetherin en route to the plasma membrane. However,
we cannot completely rule-out that Vpu could interact with
endocytosed Tetherin in the TGN and prevent its recycling back
to the cell-surface, given that previous data from the Spearman
group demonstrated a requirement for the recycling endosomes in
Vpu function [48]. Furthermore, recent studies reported that AP-2
depletion [12] or over-expression of DN mutant of Dynamin
(Dyn2-K44A) [35] could partially interfere with Vpu-mediated
down-regulation of Tetherin expression from the cell-surface.
Indeed, since Vpu is expressed from a Rev-dependent bicistronic
mRNA encoding Env and consequently is made late during the
virus life cycle [49], the direct removal of Tetherin from the
plasma membrane via endosomal trafficking may be critical to
ensure a rapid and efficient neutralization of the restriction on
HIV-1 release. It is nevertheless surprising that mutation of the
Tetherin dual Tyrosine-based endocytosis motif did not affect the
ability of Vpu to counteract Tetherin-mediated restriction of HIV-
1 particle release. Perhaps co-expressing transiently the two
proteins simultaneously may not adequately reflect physiological
conditions given that Tetherin is normally already present at the
plasma membrane when Vpu is expressed. Alternatively, it is also
possible that sequestration of newly synthesized Tetherin in the
TGN may rapidly clear the restriction factor from its site of virion-
tethering action at the plasma membrane depending on the
physiologic rate of Tetherin turnover at the plasma membrane.
More studies will be required to assess whether Vpu affects
Tetherin trafficking at a pre- or/and post-endocytic step.
Vpu-mediated sequestration of Tetherin in the TGN could be
complemented by b-TrCP-dependent degradation processes, thus
enhancing Tetherin antagonism. It is conceivable that Vpu by
forming a complex with b-TrCP and Tetherin in the membrane of
the TGN could potentially induce ubiquitination via interaction
with the SCF
b-TrCP E3 ubiquitin ligase. This ubiquitination event
could either enhance the sequestration by preventing Tetherin
recycling to the cell-surface or/and targets it to lysosomes for
degradation (Fig. 10). Our data indicating that Vpu causes a re-
localization of the cellular pool of Tetherin in the TGN, where
indeed the two proteins strongly co-localize, suggests that Vpu
affects Tetherin trafficking and potentially its degradation from a
post-ER compartment(s), and as such is difficult to reconcile with a
mechanism of proteasomal degradation of the antiviral factor
through the cellular ER-associated degradation (ERAD) pathway
[30,31,34]. However, given the fact that Vpu induces degradation
of the CD4 receptor in the ER by an ERAD-like mechanism [25],
it is still possible that some proteasomal degradation in the ER
may contribute to Tetherin depletion. Whether Vpu and Tetherin
trafficking cross each other in the TGN, thus permitting a physical
interaction between the two proteins, remains to be determined. In
this regard, it is interesting to note that recent data from our
laboratory have shown that the ability of Vpu to suppress
Tetherin-mediated restriction of HIV-1 particle release was linked
to its localization in the TGN [40]. Further studies aimed at
identifying the determinants regulating Vpu trafficking and
localization in the TGN will likely shed light on this mechanism.
HIV-1 Vpu appears to share the ability to sequester Tetherin in
the TGN with other Tetherin antagonists, namely HIV-2 Rod and
SIVtan Env. Like HIV-1 Vpu, HIV-2 Rod Env was recently
Figure 10. Model of Vpu-mediated down-regulation of Tetherin from the cell-surface. In absence of Vpu, Tetherin traffics along the
secretory pathway and reaches the plasma membrane. The protein is endocytosed, transported to the TGN and is then recycled back to the cell-
surface. In presence of Vpu, Tetherin is forming complexes with the viral protein in the membrane of the ER. Recruitment of SCF
b-TrCP by Vpu leads to
ubiquitination and proteosomal degradation of a fraction of Tetherin. Tetherin escaping degradation exits the ER. In the membrane of the TGN, Vpu
binds endocytosed Tetherin and/or Tetherin arriving from the ER and causes the sequestration of the restriction factor. Subsequently, Vpu induces
Tetherin ubiquitination through the recruitment of SCF
b-TrCP, thus targeting the ubiquitinated proteins to lysosomal degradation.
doi:10.1371/journal.ppat.1000856.g010
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Tetherin in the TGN, although in the case of HIV-2 Env, no
evidence of Tetherin degradation was observed [21]. Similarly,
SIVtan Env was also shown to downregulate cell-surface Tetherin
by sequestering the restriction factor in intracellular compart-
ment(s) [22]. Collectively, these findings suggest a common
mechanism of antagonism that results in TGN trapping, which
can be augmented by the induction of degradation in the case of
Vpu. Given the powerful restrictive effects of human Tetherin on
HIV production, this dual mechanism of antagonism mediated by
Vpu may have provided HIV-1 with stronger countermeasures to
antagonize Tetherin. This genetic and functional divergence
between HIV-1 and HIV-2 may perhaps account for the different
virulence properties displayed by these two closely related viruses
[21,50]. Future studies on the role of Tetherin antagonism in the
pathogenesis of primate immunodeficiency virus will likely shed
light on the contribution of this innate antiviral factor in the
control of viral infection and spread in vivo and will reveal whether
enhancing the antiviral activity of Tetherin is a valid option to
thwart HIV-1 replication.
Materials and Methods
Ethics statement
Polyclonal rabbit antibodies against human Tetherin were
produced according to animal experimentation research protocols
approved by the Animal Care Committee of the Institut de
recherches cliniques de Montreal and in accordance with Canadian
Council on Animal Care (CCAC) guidelines and policies.
Antibodies and chemical compounds
Anti-Vpu rabbit polyclonal serum was described previously
[40]. Anti-Tetherin rabbit polyclonal serum was generated by
immunization of rabbits with a bacterially-produced Glutathione-
S-transferase (GST) fusion protein containing a polypeptide
corresponding to amino-acids 40 to 180 of human Tetherin.
Rabbit pre-immune serum was collected prior to rabbit immuni-
zation. Monoclonal anti-HA (clone 12CA5), anti-p24 (catalog no.
HB9725) and anti-myc (clone 9E10) Abs were isolated from the
supernatants of cultured hybridoma cells obtained from the
American Type Culture Collection (ATCC). The monoclonal
anti-gp120 antibody [51,52] was obtained from NIH AIDS
research and Reference Reagent Program. All secondary Alexa-
conjugated IgG Abs were obtained from Invitrogen. Sheep anti-
TGN46 (Serotec), mouse anti-BST2 (Abnova), anti-actin Abs
(Sigma), pronase (Calbiochem), PNGase (New England Biolabs),
BFA, paraformaldehyde (PFA) and chlorpromazine (Sigma) were
all obtained from commercial sources. All reagents were stored
according to the manufacturer’s instructions.
Cells and transfection
HEK 293T, HeLa and Cos-7 cells were obtained from ATCC.
All cells were maintained as described previously [40]. HEK 293T
and HeLa cells were transfected using the calcium-phosphate
method and lipofectamine 2000 (Invitrogen), respectively. Func-
tional and biochemical analyses were performed 48h post-
transfection. Empty plasmid DNA was added to each transfection
to keep the amount of transfected DNA constant.
Plasmid constructs
HxBH10-vpu+ and HxBH10-vpu- are two infectious molecular
clones of HIV-1 that are isogenic except for the expression of Vpu
[53]. HxBH10-vpu S52D,S56D, SVCMV-vpu- and SVCMV-vpu+
were previously described, [25]. HxBH10-vpu KSL, HxB10-vpu RD
and SVCMV-vpu S52D,S56D were generated by PCR-based site-
directed mutagenesis [40]. The pcDNA/Myc-His-b-TrCP plas-
mid was kindly provided by Dr. Richard Benarous [27]. To
generate pcDNA-Tetherin and pCMV-HA-Tetherin, the human
Tetherin open reading frame was amplified by PCR from pCMV-
SPORT6-hBST2 plasmid (Open Biosystems) and cloned into
pcDNA3.1/Hygro (+) (Invitrogen) and pCMV-HA (Clontech).
The agmTetherin open reading frame was amplified from Cos-7
cells mRNA using RT-PCR as described [29]. Tetherin chimeras
were designed according to the structure prediction from Kupzig
and Banting [4]. All Tetherin genes were inserted into
pcDNA3.1/Hygro (+) using NheI and Asp718 restriction sites or
into the pCMV-HA plasmid using BglII and Asp718 restriction
sites to generate pcDNA-Tetherin and pCMV-HA-Tetherin
constructs, respectively. pCMV-HA-Tetherin Y6Y8 and pCMV-
HA-Tetherin DGI,T45I were generated by PCR-based site-
directed mutagenesis. The vesicular stomatitis virus (VSV)
glycoprotein G-expressing plasmid, pSVCMVin-VSV-G, was
previously described [54]. The pQBI25 GFP-expressing plasmid
was obtained from Qbiogene.
Steady-state detection of proteins by western blot
Transfected HeLa or HEK 293T cells were lysed in CHAPS
lysis buffer (50 mM Tris, 5 mM EDTA, 100 mM NaCl, 0.5%
CHAPS, pH 7.2) or in radio-immunoprecipitation assay (RIPA-
DOC) buffer (10 mM Tris pH 7.2, 140 mM NaCl, 8 mM
Na2HPO4, 2 mM NaH2PO4, 1% Nonidet-P40, 0.5% sodium
dodecyl sulfate, 1.2 mM deoxycholate), respectively. Proteins from
lysates were resolved on 12.5% SDS-PAGE, electro-blotted and
analyzed by western blot as described previously [40].
Pulse-chase and radio-immunoprecipitation experiments
Pulse-chase experiments were perfomed as described previously
[40]. Briefly, transfected HEK 293T or HeLa cells infected with
VSV-G-pseudotyped HxBH10-derived virus at a MOI of 1 were
pulse-labeled for 30 min and 2 h respectively, with 800 mCi/ml of
[
35S]methionine and [
35S]cysteine (Perkin Elmer) and chased for
different interval of times. Following lysis of radio-labeled cells in
RIPA-DOC, lysates were first pre-cleared with protein A
sepharose beads coated with pre-immune rabbit serum for 1 h.
Pre-cleared cell lysates were then incubated with anti-Tetherin
Abs for 2 h at 4uC prior to immunoprecipitation using protein A
sepharose beads. In HEK 293T cells, Vpu proteins were
sequentially immunoprecipitated using the same method. Labeled
proteins were analyzed by SDS-PAGE and autoradiography.
PNGase treatment
Cells were lysed in RIPA-DOC. Tetherin-containing lysates were
incubated with anti-Tetherin Abs for 2 h at 4uC prior to addition of
protein A sepharose beads. Following an incubation of 2 h at 4uC,
beads were isolated by centrifugation, washed with denaturing
buffer(New England Biolabs),resuspended indenaturingbufferand
then boiled at 95uC for 10 min. The supplied reaction buffer was
added along with NP-40 (0.1%) according to the manufacturer’s
suggestion. Samples were then digested with 1500 units of PNGase
(New England Biolabs) at 37uC for 3 h. Control samples were
incubated without the enzyme. Proteins were eluted from beads by
boiling in an equal volume of sample buffer for 10 min and
analyzed by immunoblotting.
Virus release assay
The virus release assay was described previously [40]. Briefly,
supernatants of transfected cells were clarified by centrifugation
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ultracentrifugation onto a 20% sucrose cushion in PBS for 2 h at
130000 g at 4uC and lysed in RIPA-DOC. Gag products were
analyzed by western blot. Viral release efficiency was evaluated by
determining the ratio between the virion-associated Gag (p24)
band signal and all intracellular Gag-related band signal using
laser scanning densitometry.
Production of VSVg-pseudotyped HIV-1 virus
HEK 293T cells were transfected with HxBH10 proviral
constructs and pSVCMVin-VSV-G as described previously [54].
Supernatants of transfected cells were clarified, filtered and
pelleted by ultracentrifugation as described above and resus-
pended in DMEM supplemented with 10% bovine serum (FBS).
Viruses were titrated using a standard MAGI assay [54].
Flow cytometry
Cells were washed in PBS, resuspended at a concentration of
1610
6cells/ml and stained with the specific anti-Tetherin serum
for 45 min at 4uC. After incubation, cells were washed and stained
using appropriate fluorochrome-coupled secondary Abs for
30 min at 4uC. Cells were then washed and fixed with 2% PFA.
Transfected GFP-expressing cells were analyzed for cell-surface
Tetherin expression by flow cytometry. Rabbit pre-immune serum
served as a staining control. Fluorescence intensities were acquired
using a FACScalibur flow cytometer (BD Biosciences) and data
was analyzed using FlowJo software v. 7.25 (Treestar). MFI values
presented in the histograms correspond to the specific signal
obtained after substraction of the MFI value from the pre-immune
control.
Internalization assay
Cells were washed in PBS, re-suspended in PBS containing the
anti-Tetherin serum at a concentration of 1610
6cells/ml and
incubated for 45 minutes at 4uC. Following washes in cold PBS,
cells were incubated at 37uC in DMEM medium supplemented
with 5% FBS for different time intervals. At each time point, cells
were harvested, washed in cold PBS and stained with the
appropriate fluorochrome-coupled secondary Abs for 30 min at
4uC. Transfected GFP-expressing cells were analyzed for cell-
surface Tetherin expression by flow cytometry.
Cell-surface Tetherin re-expression assay
Cells were harvested, washed in PBS, re-suspended at a
concentration of 1610
6 cells/ml in PBS-pronase 0.05% and
incubated for 30 minutes at 37uC. Cold DMEM containing 10%
FBS was added to block surface protein proteolysis. Cells were then
washed, incubated at 37uC for different time intervals and stained
for cell-surface Tetherin as described above. Expression of Tetherin
at the cell-surface of transfected GFP-positive and untransfected
GFP-negative cells was analyzed by flow cytometry.
Confocal microscopy
HeLa cells were infected with VSV-G-pseudotyped HxBH10-
derived viruses at a MOI of 0.125. Forty-eight hours post-
infection, cells were immunostained with anti-Tetherin Abs
(Abnova) for 30 min at 4uC, washed in cold PBS, fixed with 4%
PFA and permeabilized with 0.2% Triton X-100. Next, cells were
incubated with anti-Tetherin (Abnova), anti-Vpu and anti-TGN46
Abs for 2 h at 37uC, washed and incubated with the appropriate
secondary Abs for 30 min at room temperature. Analyses were
performed with a LSM710 laser scanning confocal microscope
(Zeiss). Quantitation of Tetherin signal was performed using the
Zeiss LSM510 software. The absolute Tetherin signal in the TGN
was determined by measuring the specific Tetherin signal in the
region delineated by the TGN46 marker on digital pictures
produced using similar acquisition time. Percentage of Tetherin
accumulating in the TGN was calculated by evaluating Tetherin
signal intensity in the TGN relative to the total Tetherin signal
intensity detected in the cell as described previously [40]. Analysis
was performed on at least 25 distinct cells.
Co-precipitation assay
For co-immnuoprecipitation of Vpu and Tetherin, transfected
HEK 293T and HeLa cells were harvested 48 h post-transfection
andlysedinRIPA-DOCorCHAPSbuffer,respectively.Fivepercent
of each lysates were preserved to control for protein expression. Cell
lysates were first pre-cleared with protein A sepharose beads coated
with pre-immune rabbit serum for 1 h at 4uC and then, incubated
with anti-Tetherin Abs for 2 h at 4uC, prior to precipitation with
protein A sepharose beads. Immunoprecipitates were analyzed for
t h ep r e s e n c eo fV p ua n dT e t h e r i nb yw e s t e r nb l o t .
For co-immunoprecipitation of Vpu and b-TrCP,HEK293T cells
were transfected with SVCMV-vpu- orSVCMV-vpu+or SVCMV-vpu
S52D,S56D and pcDNA/Myc-His-b-TrCP. Transfected cells were
then radiolabelled with 800 mCi/ml of [
35S]methionine and
[
35S]cysteine (Perkin Elmer) and lysed in CHAPS buffer. Lysates
werefirstpre-clearedwithproteinAsepharosebeadscoatedwithpre-
immune rabbit serum for 1 h. Pre-cleared cell lysates were then
incubated with anti-myc Abs for 2 h at 4uCp r i o rp r e c i p i t a t i o nu s i n g
protein A sepharose beads. Vpu was then sequentially immunopre-
cipitated using anti-Vpu Abs using the same method. Labeled
proteins were analyzed by SDS-PAGE and autoradiography.
Scanning and quantitation
Scans were performed on a Duoscan T1200 scanner (AGFA)
followed by densitometric quantitation using the Image Quant 5.0
software (Molecular Dynamics). Statistical analysis was performed
using a paired Student’s t test, and statistical significance was
considered at p,0.001.
Accession numbers
NCBI reference number for HxBH10 Vpu and human
Tetherin proteins are P69699 and AAH33873, respectively.
Genebank accession number for agm Tetherin is FJ943430.
Supporting Information
Figure S1 Characterization of the Vpu S52D,S56D mutant. (A)
Association of Vpu with b-TrCP. HEK 293T cells were
transfected with the indicated Vpu-expressing constructs and the
myc-b-TrCP-encoding plasmid pcDNA/Myc-His-b-TrCP. Forty-
eight hours post-transfection, cells were radio-labeled for 2h and
lysed prior to sequential immunoprecipitation using anti-myc and,
subsequently, anti-Vpu Abs. Co-immunoprecipitated proteins
were separated by SDS-PAGE and analyzed by autoradiography.
(B) Effect of Vpu S52D,S56D on Tetherin cell-surface expression.
HeLa cells were transfected with the indicated HxBH10 proviral
constructs and a GFP-expressing plasmid. Cell-surface Tetherin
expression was analyzed on GFP-positive cells by flow cytometry,
48h post-transfection. MFI values are shown beside the histogram.
Filled histogram: pre-immune control; dashed line: HxBH10-vpu-;
full black line: HxBH10-vpu+; full grey line: HxBH10-vpu
S52D,S56D. (C) Effect of Vpu S52D,S56D on HIV-1 particle
release. HeLa cells were transfected with the indicated HxBH10
proviral constructs. Cells and virus-containing supernatants were
collected 48h post-transfection, lysed and analyzed for the
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specific Abs. (D) Quantitation of virus particle release. Bands
corresponding to Gag products in cells and virus particles were
scanned by laser densitometry. The relative virus particle release
efficiency was determined as described in the Materials and
Methods and calculated as a percentage of the HxBH10-vpu+ virus
release (100%). The error bars represent the standard deviation
from the mean of three independent experiments.
Found at: doi:10.1371/journal.ppat.1000856.s001 (0.35 MB TIF)
Figure S2 Functional analysis of Tetherin chimeric proteins and
the DGI,T45I mutant. (A) Design of Tetherin chimeric proteins
and the human Tetherin DGI-T45I mutant. Cytoplasmic (Cyto),
TM, coiled-coil and GPI domain as well as glycosylation and
cleavage sites (dashed line) are represented. White: human
Tetherin; grey: agm Tetherin. The amino-acid sequence of the
mutant Tetherin DGI,T45I within the TM domain is shown
below. Dots indicate deleted residues while hyphens indicate
similar residues. (B-E) HEK 293T cells were transfected with the
specified HxBH10 proviral constructs and the indicated plasmids
expressing (B) native or (D) HA-tagged Tetherin proteins. Forty-
eight hours post-transfection, cells and virus-containing superna-
tants were harvested, lysed and proteins were analyzed by western
blot using specific Abs. (C and E) Quantitation of B and D,
respectively. Bands corresponding to Gag products in cells and
viral particles of panels B or D were scanned by laser
densitometry. The virus particle release efficiency was determined
as described in the Materials and Methods and calculated as a
percentage of the HxBH10-vpu+ release (100%) in absence of
ectopically-expressed Tetherin. Error bars represent the standard
deviation from the mean of two independent experiments.
Found at: doi:10.1371/journal.ppat.1000856.s002 (0.82 MB TIF)
Figure S3 Functional analysis of Vpu mutants in HEK 293T
cells. HEK 293T cells were transfected with plasmids encoding
native Tetherin, the indicated HxBH10 proviral constructs and a
GFP-expressing plasmid. (A) Forty-eight hours post-transfection,
cells and virus-containing supernatant were harvested, lysed and
proteins were analyzed by western blot using specific Abs. (B) In
parallel, cell-surface Tetherin expression was analyzed on GFP-
positive cells by flow cytometry. Geo mean values (depicted as
MFI) are presented in the histograms. Filled histogram: pre-
immune control; dashed line: HxBH10-vpu-; full black line:
HxBH10-vpu+; dotted line: HxBH10-vpu KSL; full grey line:
HxBH10-vpu RD.
Found at: doi:10.1371/journal.ppat.1000856.s003 (0.42 MB TIF)
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